Recent advances in corticosteroids for the treatment of asthma

Current Opinion in Investigational Drugs

Volumn 3, Issue 8, 2002, Pages 1149-1156

  Bhalay, Gurdip ^a   Sandham, David A ^a  

^a NOVARTIS HORSHAM RESEARCH CENTRE   (United Kingdom)

Author keywords

Allergic rhinitis; Asthma; Corticosteroids; Dissociated steroids; Glucocorticoid receptor; Soft steroids

Indexed keywords

A 222977; AL 438; BECLOMETASONE 17 MONOPROPIONATE; BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CHLOROFLUOROCARBON; CHOLINERGIC RECEPTOR BLOCKING AGENT; CICLESONIDE; CORTICOSTEROID; DEXAMETHASONE; EP 00393698; FLUNISOLIDE; FLUOCORTOLONE; FLUORINATED HYDROCARBON; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; GR 215864X; GW 215864X; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LONG ACTING DRUG; LOTEPREDNOL ETABONATE; MOMETASONE FUROATE; NS 126; PREDNISOLONE; PRODRUG; ROFLEPONIDE PALMITATE; RPR 106541; RU 24858; SHORT ACTING DRUG; STEROID; THEOPHYLLINE; TIPREDANE; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADRENAL CORTEX INSUFFICIENCY; AEROSOL; AREA UNDER THE CURVE; ASTHMA; BONE DISEASE; CANDIDIASIS; CATARACT; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE CONTROL; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DYSPHONIA; FIRST PASS EFFECT; GLAUCOMA; GROWTH RETARDATION; HUMAN; HYPERTENSION; INFLAMMATION; LONG TERM CARE; NONHUMAN; OSTEOPOROSIS; PRIMARY HEALTH CARE; REVIEW; SIDE EFFECT; SKIN DISEASE; SORE THROAT; SYMPTOM; WEIGHT GAIN; WEIGHT REDUCTION;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ANTI-ASTHMATIC AGENTS; HUMANS; PATENTS;

EID: 0036707350     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Barnes PJ, Pedersen S, Busse WW: Efficacy and safety of inhaled corticosteroids. New developments. Am J Resp Crit Care Med (1998) 157:S1-S53.
2. Umland SP, Schleimer RP, Johnston SL: Review of the molecular and cellular mechanisms of action of glucocorticoids for use in asthma. Pulm Pharmacol Ther (2002) 15:35-50. A comprehensive up-to-date review of the molecular biology of GR actions.
3. Adcock IM. Molecular mechanisms of glucocorticosteroid actions. Pulm Pharmacol Ther (2000) 13:115-126.
4. Kagoshima M, Wilcke T, Ito K, Tsaprouni L, Barnes PJ, Punchard N, Adcock IM: Glucocorticoid-mediated transrepression is regulated by histone acetylation and DNA methylation. Eur J Pharmacol (2001) 429:327-334.
5. Buchman AL: Side effects of corticosteroid therapy. J Clin Gastroenterol (2001) 33:289-294.
6. Pedersen S: Do inhaled corticosteroids inhibit growth in children? Am J Resp Crit Care Med (2001) 164:521-535.
7. Israel E, Banerjee TR, Fitzmaurice GM, Kotlov TV, LaHive K, LeBoff MS: Effects of inhaled glucocorticoids on bone density in premenopausal women. New Engl J Med (2001) 345:941-947.
8. Nelson HS, Stricker W, Casale TB, Raff H, Fourre JA, Aron DC, Newman KB: A comparison of methods for assessing hypothalamic-pituitary-adrenal (HPA) axis activity in asthma patients treated with inhaled corticosteroids. J Clin Pharmacol (2002) 42:319-326.
9. Szefler SJ, Martin RJ, King TS, Boushey HA, Cherniack RM, Chinchilli VM, Craig TJ, Dolovich M, Drazen JM, Fagan JK, Fahy JV et al: Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol (2002) 109:410-418. A carefully designed clinical study to compare ICS efficacy and side effects of beclamethasone dipropionate and fluticasone propionate.
10. Elks J, Phillipps GH: Discovery of a family of potent topical antiinflammatory agents. In: Medicinal Chemistry. Roberts SM, Price BJ (Eds), Academic Press, London, UK (1985):167-188.
11. Derendorf H, Hochaus G, Meibohm B, Moellmann H, Barth J: Pharmacokinetics and pharmacodynamics of inhaled corticosteroids. J Allergy Clin Immunol (1998) 101:S440-S446.
12. Daley-Yates PT, Price AC, Sisson JR, Pereira A, Dallow N: Beclomethasone dipropionate: Absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration. Br J Clin Pharmacol (2001) 51:400-409.
13. Staresinic AG, Sorkness CA: Fluticasone propionate: A potent inhaled corticosteroid for the treatment of asthma. Exp Opin Pharmacother (2000) 1:1227-1224.
14. Miller-Larsson A, Mattsson H, Hjertberg E, Dahlback M, Tunek A, Brattsand R: Reversible fatty acid conjugation of budesonide. Novel mechanism for prolonged retention of topically applied steroid in airway tissue. Drug Metab Disp (1998) 26:623-630.
15. Vanden Burgt JA, Busse WW, Martin RJ, Szefler SJ, Donnell D: Efficacy and safety overview of a new inhaled corticosteroid, QVAR (hydrofluoraalkane-beclomethasone extrafine inhalation aerosol), in asthma. J Alergy Clin Immunol (2000) 106:1210-1226.
16. 2 agonists and inhaled corticosteroids. Eur Respir J (2002) 19:182-191.
17. Sharpe M, Jarvis B: Inhaled mometasone furoate: A review of its use in adults and adolescents with persistent asthma. Drugs (2001) 61:1325-1350.
18. Mealy NE, Bayes M, Castaner J: Ciclesonide: Treatment of allergic rhinitis antiallergy/antiasthmatic BY-9010 B-9207-015. Drugs Fut (2001) 26:1033-1039.
19. Warne PJ: The discovery and clinical development of RPR 106541. An airway-selective steroid for the treatment of asthma. Emerg Drugs (2000) 5:231-239.
20. Bodor N, Buchwald P: Soft drug design: General principals and recent applications. Med Res Rev (2000) 20:58-101. An excellent review on the soft drug design concept.
21. Mützel W: Pharmacokinetics and biotransformation of fluocortin butyl ester in man. Arzneimittelforschun (1977) 27:2230-2233.
22. Burge S, Efthimiou J, Turner-Warwick M, Nelmes PTJ: Double blind trial of inhaled beclomethasone dipropionate and fluocortin butyl ester in allergen-induced immediate and late asthmatic reactions. Clin Allergy (1982) 12:523-531.
23. Gerhards E, Nieuweboer B, Schulz G, Gibian H, Berger D, Hecker W: Stoffwechsel von 6α-fluor-16α-methyl-pregna-1,4-diene-11β,21-diol-3,20-dion (fluocortolon) beim menschen. Acta Endocr (1971) 68:98-126.
24. Thalén A, Andersson PH, Andersson PT, Axelsson B, Edsbúcker S, Brattsand R: Prospects for developing inhaled steroids with extrahepatic metabolism - 'soft steroids'. In: Airway Activity and Selectivity of Inhaled Steroids in Asthma. Schleimer RP, O'Byrne P, Szefer S, Brattsand R (Eds), Marcel Dekker, New York, NY, USA (2002):521-538.
25. Poppe H, Marx D, Heer S, Szelenyi I: Effects of loteprednol etabonate on TNFα and GM-CSF release in vitro and on late phase eosinophilia in guinea pigs administered intracheally as a dry powder. Am J Respir Crit Care Med (1998) 157 (Suppl):A522.
26. Bodor N, Loftsson T, Wu W-M: Metabolism distribution and transdermal permeability of a soft steroid, loteprednol etabonate. Pharm Res (1992) 9:1275-1278.
27. Hochhaus G, Chen L-S, Ratka A, Druzgala P, Howes J, Bodor N, Derendorf H: Pharmacokinetic characterization and tissue distribution of the new glucocorticoid soft drug loteprendol etabonate in rats and dogs. J Pharm Sci (1992) 81:1210-1215.
28. Angell RM, Biggadike, Farrell RM, Flack SS, Hancock AP, Irving WR, Lynn SM, Procopiou PA: Novel glucocorticoid antedrugs possessing a 21-(γ-lactone) ring. J Chem Soc Perkin Trans 1 (2002) 6:831-839. Gives leading references to publications describing the role of the enzyme paraoxonase.
29. Jaffuel D, Demoly P, Gougar C, Balaguer P, Mautino G, Godard P, Bousquet J, Mathieu M: Transcriptional potencies of inhaled glucocorticoids. Am J Resp Crit Care Med (2000) 162:57-63.
30. Vayssiere BM, Dupont S, Chocquart A, Petit F, Garcia T, Marchandeau C, Gronemeyer, Resche-Rigon M: Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit antiinflammatory activity in vivo. Mol Endocrinol (1997) 11:1245-1255.
31. Belvisi MG, Wick SL, Battram CH, Bottoms SEW, Redford JE, Woodman P, Brown TJ, Webber SE, Foster ML: Therapeutic benefit of a dissociated glucocorticoid and the relevance of in vitro separation of transrepression from transactivation activity. J Immunol (2001) 166:1975-1982. A thorough in vivo study of RU-24858, whcih casts some doubt on the dissociated steroid concept.
32. Coghlan MJ, Kym PR, Elmore SW, Wang AX, Luly JR, Wilcox D, Stashko M, Lin C-W, Miner J, Tyree C, Nakane M et al: Synthesis and characterization of non-steroidal ligands for the glucocorticoid receptor: Selective quinoline derivatives with prednisolone-equivalent functional activity. J Med Chem (2001) 44:2879-2885. The first reported non-steroidal GR agonists.
33. Elmore SW, Coghlan MJ, Anderson DD, Pratt JK, Green BE, Wang AX, Stashko MA, Lin CW, Tyree CM, Miner JN, Jacobsen PB et al: Nonsteroidal selective glucocorticoid modulators: The effect of C-5 alkyl substitution on the transcriptional activation/repression profile of 2,5-dihydro-10-methoxy-2,2,4-trimethyl-1H-[1]benzopyrano[3,4-f]quinolines. J Med Chem (2001) 44:4481-4491.
34. Rosen J, Miner JN: Improving the utility of steroidal antiinflammatories: Identification of selective glucocorticoid receptor modulators. Curr Med Chem: Immunol, Endocrine Metabol Agents (2002) 2:11-22. A review of the Abbot/Ligand approach to dissociated steroids.
35. SS Pharmaceutical Co Ltd (Komoto T, Okawa J, Ogawa Y, Sato S, Taido N, Kuraishi T): Preparation of dexamethasone 17α-cyclopropanecarboxylate derivatives as antiinflammatories. EP-00393658 (1990).
36. Glaxo Group Ltd (Biggadike K, Coote SJ, Nice RK) 6α9α-difluoro-17α-(2-furanylcarboxy)oxy- 11β-hydroxy-16α-methyl-3-oxo androst-1,4-diene-17-carbothioic acid S-fluoromethyl ester as an antiinflammatory agent. WO-00212265 (2002).
37. Novartis AG (Cuenoud B, Beattie D, Keller TH, Pilgrim GE, Sandham DA, Watson SJ): Preparation of 9-chloro-6-fluoro-11,17-dihydroxy-16-methyl-3-oxo-androsta-1,4-dien-17-carboxyli c acid-methylester derivatives as antiinflammatory agents. WO-00200679 (2002).
38. Glaxo Group Ltd (Biggadike K, Farrell RM): Preparation of 21-(2-oxo-tetrahydrofuranyl)-thio pregnane derivatives and their pharmaceutical compositions for use as antiinflammatory and antiallergic agents. WO-09724367 (1997).
39. Matrix Therapeutics Ltd (Barr SA, McKervey MA, Miel HJP, Ray DW, Brass AM): Selective glucocorticoid receptor agonists. WO-00236606 (2002).
40. Abbott Laboratories/Ligand Pharmaceuticals Inc (Coghlan MJ, Elmore SW, Kort ME, Kym PR, Moore JL, Pratt JK, Wang AX, Edwards JP, Jones TK): Preparation of glucocorticoid-selective antiinflammatory agents. WO-09941256 (1999).
41. Abbott Laboratories/Ligand Pharmaceuticals Inc (Coghlan MJ, Kort ME, Edwards JP, Jones TK): Preparation of glucocorticoid-selective antiinflammatory agents. WO-00994125 (1999).
42. Abbott Laboratories/Ligand Pharmaceuticals Inc (Coghlan MJ, Elmore SW, Kort ME, Kym PR, Moore JL, Pratt JK, Wang AX, Edwards JP, Jones TK): Preparation of glucocorticoid-selective benzopyrano[3,4-f]quinolines as antiinflammatory agents. WO-00202565 (2002).